Clinical Trials Logo

CAR clinical trials

View clinical trials related to CAR.

Filter by:

NCT ID: NCT04691713 Recruiting - Solid Tumor Clinical Trials

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This study is a clinical study of CD276 CAR-T in the treatment of patients with advanced solid tumors. The purpose is to evaluate the safety and effectiveness of targeting CD276 auto-chimeric antigen receptor T cells in the treatment of CD276-positive advanced solid tumors.

NCT ID: NCT03267173 Recruiting - Pancreatic Cancer Clinical Trials

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

Start date: June 15, 2017
Phase: Early Phase 1
Study type: Interventional

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. It has become the fourth tumor treatment model after traditional tumor therapies (surgery, chemotherapy, radiotherapy) . Mesothelin, PSCA, CEA, HER2, MUC1 and EGFRvIII are potential targets and spectacular paradigm in the diagnosis and treatment of pancreatic cancer. This study is for evaluation of the safety and efficacy of Mesothelin, PSCA, CEA, HER2, MUC1, EGFRvIII targeted and other CAR-T cell immunotherapy for pancreatic cancer.

NCT ID: NCT03198546 Recruiting - Clinical trials for Hepatocellular Carcinoma

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.